Hormonal
Women with type 2 diabetes face a significantly higher relative risk of cardiovascular disease and mortality compared to men, despite often being diagnosed at a lower body mass index and younger age.
If you are a woman with type 2 diabetes, your risk of heart disease and death is higher relative to a man with diabetes, even if your weight is lower. This risk is amplified by hormonal changes like menopause and pregnancy history. You need aggressive management of blood pressure, lipids, and glucose, potentially starting earlier than guidelines might suggest for men, because your body may have more advanced heart vessel damage at the time of diagnosis.
Women with type 2 diabetes show greater relative risk of CVD and mortality than men... women with type 2 diabetes are more likely to have advanced atherosclerosis than men at the time of diagnosis
Why this rating
Based on a narrative review citing multiple large cohort studies, Mendelian randomization analyses, and meta-analyses.
Source
Sex differences in type 2 diabetes
Alexandra Kautzky‐Willer et al. · Diabetologia · 2023
DOI 10.1007/s00125-023-05891-x
More from this paper
- Gestational diabetes mellitus (GDM) is the most prominent independent risk factor for the progression to type 2 diabetes in women, increasing the relative risk by approximately 8.3-fold.Strong
- Visceral adipose tissue (VAT) is a stronger independent risk factor for type 2 diabetes in women than in men, making waist circumference a more reliable predictor of risk in women.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →